Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5290839
Max Phase: Preclinical
Molecular Formula: C26H43N7O12S2
Molecular Weight: 709.80
Associated Items:
ID: ALA5290839
Max Phase: Preclinical
Molecular Formula: C26H43N7O12S2
Molecular Weight: 709.80
Associated Items:
Canonical SMILES: CC(C)C[C@@H]1NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)O)NC1=O
Standard InChI: InChI=1S/C26H43N7O12S2/c1-11(2)6-15-23(41)33-18(26(44)45)10-47-46-9-13(27)21(39)28-12(3)20(38)31-16(7-34)24(42)29-14(4-5-19(36)37)22(40)32-17(8-35)25(43)30-15/h11-18,34-35H,4-10,27H2,1-3H3,(H,28,39)(H,29,42)(H,30,43)(H,31,38)(H,32,40)(H,33,41)(H,36,37)(H,44,45)/t12-,13-,14-,15-,16-,17-,18-/m0/s1
Standard InChI Key: QGYRXMHEJTXRFR-GOMYCMKKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 709.80 | Molecular Weight (Monoisotopic): 709.2411 | AlogP: -4.38 | #Rotatable Bonds: 8 |
Polar Surface Area: 315.68 | Molecular Species: ACID | HBA: 13 | HBD: 11 |
#RO5 Violations: 3 | HBA (Lipinski): 19 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.46 | CX Basic pKa: 7.66 | CX LogP: -7.79 | CX LogD: -10.91 |
Aromatic Rings: 0 | Heavy Atoms: 47 | QED Weighted: 0.11 | Np Likeness Score: 1.06 |
1. Cuffaro D, Ciccone L, Rossello A, Nuti E, Santamaria S.. (2022) Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition., 65 (20.0): [PMID:36250680] [10.1021/acs.jmedchem.2c01177] |
Source(1):